Navigation Links
Treatment approach to human Usher syndrome: Small molecules ignore stop signals
Date:7/1/2011

This release is available in German.

Usher syndrome is the most common form of combined congenital deaf-blindness in humans and affects 1 in 6,000 of the population. It is a recessive inherited disease that is both clinically and genetically heterogeneous. In the most severe cases, patients are born deaf and begin to suffer from a degeneration of the retina in puberty, ultimately resulting in complete blindness. These patients experience major problems in their day-to-day life. While hearing loss can be compensated for with hearing aids and cochlea implants, it has not proven possible to develop a treatment for the associated sight loss to date. Researchers at Johannes Gutenberg University Mainz (JGU) in Germany have now developed a new treatment approach to this disease.

In previously conducted research into this subject, the research team headed by Professor Uwe Wolfrum of the Institute of Zoology at Mainz University had already gained insight into of the fundamental molecular processes and mechanisms causing this debilitating syndrome. Using the results of this successful basic research, the Usher treatment team in Mainz headed by Dr Kerstin Nagel-Wolfrum has now evaluated potential ocular treatment options. Their attention was focused on a mutation identified in a specific German family known to develop the most severe form of Usher syndrome. This mutation is a so-called nonsense mutation in the USH1C gene, which leads to the generation of a stop signal in a DNA base, resulting in premature termination of protein synthesis.

The Mainz research team has now published its latest work on pharmacogenetic strategies for the treatment of Usher syndrome patients with nonsense mutations in the May edition of the journal Human Gene Therapy. The researchers were able to show that a small molecule known as PTC124 (Ataluren) causes the stop
'/>"/>

Contact: Dr. Kerstin Nagel-Wolfrum
nagelwol@uni-mainz.de
49-613-139-20131
Johannes Gutenberg Universitaet Mainz
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. IOF calls for improved strategies to close the treatment gap and reduce future burden of fractures
2. Scripps Research scientists awarded $2.2 million to develop treatment for multi-drug addiction
3. Potential treatment for deadly E. coli disease
4. Research reveals effectiveness of seizure treatments for children with autism
5. Therapies to improve biochemical functions hold promise as treatments for autism
6. Cancer drug holds promise as first treatment for common, inherited dementia
7. Arthritis patients taking newer treatments do not have an overall increased cancer risk
8. Undertreatment of cardiovascular disease in rheumatoid arthritis patients following a heart attack
9. Several abstracts on gout reveal true burden of disease and highlight promising new treatments
10. Targeted adalimumab treatment can optimize long-term outcomes for patients with early RA
11. Recycling of Alzheimers proteins could be key to new treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... microcontroller (MCU) and touch technology solutions, today launched the ... with the widest V cc range from ... accuracy and faster I 2 C bus communication speeds, ... EEPROM memory making them ideal for consumer, industrial, computer, ...
(Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
(Date:11/18/2014)...   EyeLock Inc. , a market leader ... USA (Safran), a leading U.S. provider of ... partnership to offer comprehensive biometric identity solutions and ... screening and financial services markets. As ... through a nationwide network of 1,100 IdentoGO® Centers.  ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... pollution from waterways with microbes instead discovered that some ... electricity. They present their findings today at the 105th ... "The bacteria are capable of continuously generating electricity at ... devices. As long as the bacteria are fed fuel ...
... Alzheimer's: targeting a key enzyme with gene therapy reversed ... been genetically engineered to develop Alzheimer's disease, scientists were ... the amount of an enzyme that is crucial for ... showing is a proof of principle that stopping the ...
... the most severe form of that group of diseases, affects ... caused by a protozoan, Leishmania infantum, transmitted by sand fly ... rapidly lead to death if no treatment is given. In ... heavily by infection. It acts as parasite reservoir for humans. ...
Cached Biology News:Pollution-eating bacteria produce electricity 2Targeting a key enzyme with gene therapy reversed course of Alzheimer's disease in mouse models 2Targeting a key enzyme with gene therapy reversed course of Alzheimer's disease in mouse models 3Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 2Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 3Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 4
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... will hold its 2015 Annual Meeting of Stockholders on ... the expected date for the Annual Meeting represents a ...
(Date:12/24/2014)... December 23, 2014 GMO corn cases ... company, Syngenta, are in the process of being consolidated ... consolidated case is In Re: Syngenta AG MIR 162 ... Court for the District of Kansas. , Management of ... handed over to U.S. District Judge John W. Lungstrum.* ...
(Date:12/24/2014)... SoundConnect’s 2015 ... introduce cutting edge communication technology, provide continued ... platform upgrades. This webinar series demonstrates online ... their quest to leverage web conferencing’s most ... SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our webinars ...
(Date:12/24/2014)... According to Ross Selinger, President of ... Global, the national office market continues to be strong, driven ... evidenced by the third quarter’s surprising 3.9% GDP, unemployment decreasing ... costs have held inflation down and the Fed is keeping ... market remaining soft. , This solid economic news is having ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... Services to Improve Safety and Quality of CareWHITE ... leading provider of specialty healthcare solutions, and Thomson ... selected by the New York State Department of ... practice utilization review program. The program examines how ...
... ALTO, Calif., April 16 Cell Biosciences, Inc., ... science researchers, today announced the launch of the ... platform for ultrasensitive characterization of cell signaling proteins. ... reproducibility, and ease-of-use for researchers studying signaling pathways ...
... Pharmaceutical companies,GlaxoSmithKline and Pfizer today announced an "innovative agreement" ... company. , The deal will see ... with GSK holding 85% of the company and Pfizer 15%. ... dilutive to GSK earnings in the first two,years but in ...
Cached Biology Technology:APS Healthcare and Thomson Reuters to Manage New York State's Medicaid Clinical Best Practices Review Program 2APS Healthcare and Thomson Reuters to Manage New York State's Medicaid Clinical Best Practices Review Program 3APS Healthcare and Thomson Reuters to Manage New York State's Medicaid Clinical Best Practices Review Program 4Cell Biosciences Launches Next-Generation Protein Characterization System 2
Request Info...
Request Info...
... ml CELLection Dynabeads (4.5 m) coated with ... antigen EpCAM and DNase Releasing Buffer. ... epithelial tumour cells directly from blood, bone ... be enriched from bone marrow. Enriched cells ...
PHOTOMAN DIRECT COPY CAMERA, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: